haloperidol (redirected from Peridol)

haloperidol /hal·o·peri·dol/ (hal″o-per´ĭ-dol) an antipsychotic agent of the butyrophenone group with antiemetic, hypotensive, and hypothermic actions; used especially in the management of psychoses and to control vocal utterances and tics of Gilles de la Tourette's syndrome; used also as the decanoate ester in maintenance therapy for psychotic disorders.

---

hal·o·per·i·dol (hl-pr-dôl, -dl)

n.

A tranquilizer used especially in the treatment of psychotic disorders, including schizophrenia.

---

haloperidol

[hal′ōper′ədôl]

a butyrophenone antipsychotic.

indications It is prescribed in the treatment of schizophrenia, in the control of tics and verbal utterance of Tourette's syndrome, in the treatment of severe behavioral problems in children, and as a sleep aid.

contraindications Parkinson's disease, concurrent administration of central nervous system depressants, liver or renal dysfunction, severe hypotension, or known hypersensitivity to this drug prohibits its use.

adverse effects There is a wide range of adverse effects. Among the more serious adverse effects are hypotension and hypersensitivity reactions. It also has comparatively high risk for a variety of extrapyramidal effects, including pseudoparkinson signs and symptoms, tardive dyskinesia, dystonia, and akathisia.

---

haloperidol

a dopamine antagonist in the brain, used as a neuroleptoanalgesic agent.

---

haloperidol

Apo-Haloperidol (CA), Dozic (UK), Novo-Peridol (CA), Peridol (CA), PMS Haloperidol (CA), Serenace (UK)

Pharmacologic class: Butyrophenone

Therapeutic class: Antipsychotic

Pregnancy risk category C

Action

Unknown. Thought to block postsynaptic dopamine receptors in brain and increase dopamine turnover rate, inhibiting signs and symptoms of psychosis.

Availability

Injection (decanoate): 50 mg/ml, 100 mg/ml

Injection (lactate): 5 mg/ml

Oral concentrate (lactate): 2 mg/ml

Tablets: 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, 20 mg

⊘Indications and dosages

➣ Symptomatic treatment of psychotic disorders or Tourette syndrome

Adults: For moderate symptoms, 0.5 to 2 mg P.O. two to three times daily. For severe symptoms or chronic or resistant disorder, 3 to 5 mg P.O. two to three times daily, to a maximum of 100 mg daily if needed. Adjust subsequent dosages carefully based on response and tolerance. Alternatively, 2 to 5 mg I.M. (lactate) may be given for prompt control of acutely agitated patient with moderate to severe symptoms; based on response, subsequent doses may be given q hour.

➣ Schizophrenia in patients who need prolonged parenteral antipsychotic therapy

Adults: For patient previously stabilized on oral haloperidol, initial I.M. dose (decanoate) is 10 to 20 times the previous daily P.O. haloperidol equivalent, depending on patient's stability on low or high P.O. dosage. Initially, I.M. dosage shouldn't exceed 100 mg. If conversion requires dosage above 100 mg, give balance in 3 to 7 days. Maintenance dosage is 10 to 15 times the previous daily P.O. dosage, depending on response.

➣ Psychotic disorders

Children ages 3 to 12 or weighing 15 to 40 kg (33 to 88 lb): 0.05 to 0.15 mg/kg/day P.O. in two or three divided doses. May be increased by 0.5 mg daily given in two or three divided doses at 5- to 7-day intervals, depending on response and tolerance.

➣ Nonpsychotic behavior disorder; Tourette syndrome

Children ages 3 to 12 or weighing 15 to 40 kg (33 to 88 lb): 0.05 to 0.075 mg/kg/day P.O. in two or three divided doses

Dosage adjustment

• Elderly or debilitated patients

Off-label uses

• Nausea and vomiting
• Infantile autism
• Intractable hiccups

Contraindications

• Hypersensitivity to drug, tartrazine, sesame oil, or benzyl alcohol (with some products)
• Severe CNS depression

Precautions

Use cautiously in:
• hepatic disease, bone marrow depression, cardiac disease, respiratory insufficiency, CNS tumors, seizures, diabetes mellitus, angle-closure glaucoma, prostatic hypertrophy
• elderly patients
• pregnant or breastfeeding patients
• children (parenteral form not recommended).

Administration

☞ Don't give decanoate form I.V.
• Administer decanoate form by deep I.M. injection using 21G needle. Two injections may be necessary; maximum volume shouldn't exceed 3 ml.
• Know that recommended interval between I.M. injections is 4 weeks.
• Dilute oral concentrate in water, soda, or juice (orange, apple, tomato) immediately before administering.
• Be aware that patient should be switched from parenteral form to oral form as soon as possible.
• Know that parenteral form is not recommended in children.

Route	Onset	Peak	Duration
P.O.	Unknown	3-6 hr	Unknown
I.V. (lactate)	Unknown	Unknown	Unknown
I.M. (decanoate)	20-30 min	30-45 min	4-8 hr

Adverse reactions

CNS: confusion, drowsiness, restlessness, extrapyramidal reactions, sedation, lethargy, insomnia, vertigo, tardive dyskinesia, seizures, neuroleptic malignant syndrome

CV: hypotension, hypertension, tachycardia, ECG changes, torsades de pointes (with I.V. use)

EENT: blurred vision, dry eyes

GI: constipation, ileus, dry mouth, anorexia

GU: urinary retention, menstrual irregularities, gynecomastia, priapism

Hematologic: anemia, leukocytosis, leukopenia

Hepatic: jaundice, drug-induced hepatitis

Metabolic: galactorrhea

Respiratory: dyspnea, respiratory depression, bronchospasm, laryngospasm

Skin: diaphoresis, photosensitivity, rash

Other: hyperpyrexia, hypersensitivity reactions

Interactions

Drug-drug. Antidepressants, antihistamines, atropine, disopyramide, phenothiazines, quinidine, other anticholinergics: additive anticholinergic effects

Antihypertensives, nitrates: additive hypotension

CNS depressants (including antihistamines, opioid analgesics, sedative-hypnotics): additive CNS depression

Epinephrine: severe hypotension and tachycardia

Levodopa, pergolide: decreased therapeutic effects of haloperidol

Lithium: acute encephalopathic syndrome

Methyldopa: dementia

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, thyroid function tests: increased values

Arterial blood gases, bicarbonate: altered values

White blood cells: increased or decreased count

Drug-herbs. Angel's trumpet, jimsonweed, scopolia: antagonism of cholinergic effects

Chamomile, hops, kava, skullcap, valerian: increased CNS depression

Nutmeg: reduced haloperidol efficacy

Drug-behaviors. Acute alcohol ingestion: additive hypotension

Patient monitoring

☞ Monitor CNS status closely, especially for seizures and neuroleptic malignant syndrome (shown by extrapyramidal symptoms, hyperthermia, and autonomic disturbances).
☞ Monitor cardiovascular status, particularly for ECG changes, blood pressure changes, torsades de pointes, and atypical rapid ventricular tachycardia, which may progress to ventricular fibrillation (with I.V. use).
• Assess respiratory status.
• Monitor liver function test results and CBC with white cell differential.
• With prolonged use, assess for tardive dyskinesia (which may occur months or even years after starting drug).

Patient teaching

• Tell patient to dilute oral concentrate with water, cola, or juice immediately before taking.
☞ Instruct patient to immediately report signs or symptoms of serious adverse reactions, such as unusual weakness, yellowing of skin or eyes, difficulty breathing, or symptoms of neuroleptic malignant syndrome (such as fever, muscle pain or rigidity, rapid or irregular pulse, increased sweating, change in urination pattern, or decreased mental acuity).
• Advise patient to minimize GI upset by eating frequent, small servings of food and drinking adequate fluids.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

---

haloperidol

Haldol^® Psychiatry A dopamine-blocking antipsychotic for treatment-refractory schizophrenia; it ↓ hallucinations, delusions, thought disturbances, ameliorates withdrawal and apathy, used to control Sx, and to prevent relapse; it may be used for Tourette syndrome Adverse effects Sedation, weight gain, extrapyramidal signs–which may be may be immediate–eg, parkinsonism, akathisia and acute dystonia, or late with long-term therapy–eg, tardive dyskinesia, 'rabbit' syndrome, orthostatic hypotension, cardiovascular, GI effects, potentially fatal neuroleptic malignant syndrome. See Neuroleptic malignant syndrome, Positive & Negative Symptom Scale, 'Rabbit syndrome, ' Schizophrenia. Cf Clozapine.